EIPR1 (Gene)

Synonyms:EARP complex and GARP complex interacting protein 1, EIPR-1, EIPR1, ENTREZ:7260, HGNC:12383, MIM:608998, NM_001330530, NM_001330531, NM_003310, NP_001317459, NP_001317460, NP_003301, TSSC1, XM_006711893, XM_011510383, XM_011510385, XM_017004818, XP_006711956, XP_011508685, XP_011508687, XP_016860307
Omim:OMIM:608998
Id:d89825c5-ad0b-5258-945e-494e99a0956f
Hgnc:HGNC:12383
Entrez:7260
Description:EARP complex and GARP complex interacting protein 1
This gene has been reported in PMID 9403053 as one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. Alignment of this gene to genomic sequence data suggests that this gene resides on chromosome 2 rather than chromosome 11. [provided by RefSeq, Dec 2008]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View EIPR1's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with EIPR1.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using EIPR1.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for EIPR1.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with EIPR1.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.